NCT02580396View on ClinicalTrials.gov

Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 16, 2016

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Metastatic Breast Cancer
Interventions
DEVICE

CanADVICE+® (smart phone app)

The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.

Trial Locations (1)

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

All Listed Sponsors
lead

Royal Marsden NHS Foundation Trust

OTHER

NCT02580396 - Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine | Biotech Hunter | Biotech Hunter